First Japanese Institution to Utilize SOPHiA GENETICS' Myeloid Plus Solution
PR94618
BOSTON, LAUSANNE, Switzerland, and HIROSHIMA, Japan, Feb. 22, 2022 /PRNewswire=KYODO JBN/ --
SOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement with Hiroshima
University, one of the top public universities in Hiroshima City, Japan, to
support their molecular profiling by next-generation sequencing (NGS) in
investigating the pathogenic variants causing different blood cancer disorders.
Logo - https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg
Hiroshima University is home to one of the largest university research
institutes in the field of radiation biomedical science in Japan. With NGS for
myeloid testing not widely available in Japan, a group of Hiroshima University
researchers tapped the SOPHiA DDM Platform [
] to assist with the clinical utility of NGS tests for myeloid malignancies.
Hiroshima University aimed to establish a framework where the NGS-based testing
would become a routine part of clinical diagnosis for myeloid neoplasms.
Following the adoption of the SOPHiA DDM Platform, Masatoshi Nishizawa from
Hiroshima University presented a research case study at the 83rd Annual Meeting
of Japanese Society of Hematology (Sendai, September 23-25, 2021). Leveraging
the SOPHiA DDM Platform's unique algorithmic capabilities, the researchers from
Hiroshima University detailed their experience with the first 24 samples of
myeloid solution collected and analyzed as part of a research project to
evaluate the clinical utility of NGS testing for myeloid malignancies. The
evaluation showed that the SOPHiA DDM platform's unique capabilities in support
of NGS testing were both useful and feasible in identifying druggable targets
and making precise diagnosis and prognosis to help benefit more patients in
Japan. The work of Hiroshima University has since been shared with Japanese
laboratories and clinicians, and the university aims to continue its evaluation
with additional samples over the next 12 months.
"SOPHiA GENETICS is committed to improving patient outcomes through the
practice of data driven medicine. We work with several oncohematology centers
around the world and are now eager to start supporting the Japanese
oncohematology network of hospitals. The more data we compute, the more benefit
we bring to all our users to ultimately accelerate the democratization of
data-driven-medicine," said Jurgi Camblong, co-founder and CEO of SOPHiA
GENETICS.
"To make a personalized treatment in the real-world practice of oncohematology
prevail, the sophistication of diagnostic gene panels is strongly desired,"
said Tatsuo Ichinohe, Director of the Department of Hematology and Oncology at
Hiroshima University Hospital. "SOPHiA GENETICS' Myeloid Plus Solution is one
of the best examples I have ever seen in terms of its ease of use and wide
coverage."
SOPHiA GENETICS' partnership with Hiroshima University follows the company's
March 2021 announcement [
] of a long-term collaboration agreement with Hitachi, Ltd. To bring clinical,
genomic, and real-world insights to more Japanese healthcare providers and
pharmaceutical and biopharmaceutical companies. In partnership with Hitachi,
discussions continue with additional Japanese institutions who may also benefit
from SOPHiA GENETICS for oncohematological cancer research.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to
establishing the practice of data-driven medicine as the standard of care and
for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a
cloud-based SaaS platform capable of analyzing data and generating insights
from complex multimodal data sets and different diagnostic modalities. The
SOPHiA DDM(TM) Platform and related solutions, products and services are
currently used by more than 780 hospital, laboratory, and biopharma
institutions globally. For more information, visit SOPHiAGENETICS.COM [
], or connect on Twitter [
], LinkedIn [
] and Instagram [
]. Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for use in
diagnostic procedures, unless specified otherwise. The information in this
press release is about products that may or may not be available in different
countries and, if applicable, may or may not have received approval or market
clearance by a governmental regulatory body for different indications for use.
Please contact support@sophiagenertics.com to obtain the appropriate product
information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking
statements. All statements other than statements of historical facts contained
in this press release, including statements regarding our future results of
operations and financial position, business strategy, products and technology,
as well as plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently available to
our management. Such statements are subject to risks and uncertainties, and
actual results may differ materially from those expressed or implied in the
forward-looking statements due to various factors, including those described in
our filings with the U.S. Securities and Exchange Commission. No assurance can
be given that such future results will be achieved. Such forward-looking
statements contained in this press release speak only as of the date hereof .
We expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to reflect any
change in our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required to do so by
applicable law. No representations or warranties (expressed or implied) are
made about the accuracy of any such forward-looking statements.
SOURCE SOPHiA GENETICS
CONTACT: Eliza Bamonti, ebamonti@sophiagenetics.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
